Background: Warfarin reduces the risk for ischemic stroke in patients with atrial fibrillation (AF) but increases the risk for hemorrhage. Dabigatran is a fixed-dose, oral direct thrombin inhibitor with similar or reduced rates of ischemic stroke and intracranial hemorrhage in patients with AF compared with those of warfarin.
because of hepatotoxicity. Dabigatran etexilate is a newer direct thrombin inhibitor that does not cause liver dysfunction (14 -16) . The RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial was an international, multicenter randomized noninferiority trial in which 18 113 patients with AF at increased risk for stroke (CHADS 2 score Ն1 or equivalent [Appendix Table 1 , available at annals.org] [17] ) were randomly assigned to receive dabigatran, 110 mg twice daily (low dose); dabigatran, 150 mg twice daily (high dose); or adjusted-dose warfarin (18) . After a median 2-year follow-up, the rates of stroke and systemic embolism were similar in the low-dose dabigatran and warfarin groups, but the low-dose dabigatran group had lower rates of intracranial hemorrhage (ICH) and major hemorrhage. Patients in the high-dose dabigatran group had lower rates of stroke, systemic embolism, and ICH compared with warfarin recipients, although rates of any major hemorrhage were similar. In October 2010, the U.S. Food and Drug Administration (19) approved high-dose dabigatran (150 mg twice daily) for prevention of stroke and systemic embolism in AF, with reduced dosing (75 mg twice daily) available for patients with severe renal impairment. Low-dose dabigatran (110 mg twice daily) was not approved.
In this study, we compared the quality-adjusted survival, costs, and cost-effectiveness of warfarin, low-dose dabigatran, and high-dose dabigatran in patients with nonvalvular AF.
METHODS

Decision Model
Using a Markov model (20) , we performed a decision analysis comparing 3 treatment strategies for the prevention of stroke in patients with AF: adjusted-dose warfarin with a target international normalized ratio (INR) of 2.0 to 3.0, twice-daily dabigatran at 110 mg (low dose), and twice-daily dabigatran at 150 mg (high dose). Our base case was a hypothetical cohort of patients 65 years or older with AF who were at increased risk for stroke (on the basis of a CHADS 2 score Ն1 or equivalent) and had no contraindications to anticoagulation. We expressed our results in quality-adjusted life expectancy, 2008 U.S. dollars, and incremental cost-effectiveness ratios (ICERs).
The health states in the model included healthy with AF, transient ischemic attack, ischemic stroke (fatal, moderate to severe, mild, or reversible), hemorrhage (fatal, moderate to severe intracranial, mild intracranial, major noncerebral, or minor noncerebral), myocardial infarction, recurrent or combined events, and death (Appendix Figure  1 , available at www.annals.org). Appendix Table 2 (available at www.annals.org) provides definitions of ischemic stroke, ICH, and myocardial infarction (21, 22) . We applied utilities and costs to each outcome over its expected duration in 2-week increments, and we discounted costs and benefits at 3% annually (23) . The risks for the adverse events included in our model were generally derived from the event rates published in the RE-LY trial unless stated otherwise (18) . We assumed that event rates for other conditions not included in our model were similar across all treatments. For all treatments, we quantified qualityadjusted life expectancy, risk for adverse events, and net cost over 35 years or until death (if that occurred earlier). Model creation and analyses were performed by using TreeAge Pro Suite 2009 (TreeAge Software, Williamstown, Massachusetts) and Microsoft Excel 2007 (Microsoft, Redmond, Washington).
Probability of Adverse Outcomes in the Decision Model
Mortality rates were adjusted for age (beginning at age 65 years). The presence of AF and antithrombotic therapy are accounted for in our model by the clinical event rates derived from the RE-LY trial (8, 18, 24 -29) .
Ischemic Stroke
In the base case, the annual rates of ischemic stroke were 1.20% for warfarin, 1.34% for low-dose dabigatran, and 0.92% for high-dose dabigatran ( Table 1 ) (18) . The rate of stroke and transient ischemic attack increased by a factor of 1.4 per decade of life (multiplicative adjustment) (8) . We defined the annual risk for ischemic stroke at 3.20% with aspirin. We assumed that 28% of ischemic neurologic events were transient ischemic attacks (34 -37) .
Hemorrhage
For the base case, the annual rate of ICH was estimated at 0.74% for warfarin, 0.23% for low-dose dabigatran, and 0.30% for high-dose dabigatran ( Table 1 ) (18) . The rate of ICH increased by a factor of 1.97 per decade of life (multiplicative adjustment) (63) . The annual rate of major hemorrhage was estimated at 3.36% with warfarin,
Context
Dabigatran is a direct thrombin inhibitor shown to be about as safe and effective as warfarin for preventing thromboembolism in patients aged 65 years or older with nonvalvular atrial fibrillation.
Contribution
This analysis suggests that dabigatran is generally costeffective as an alternative to warfarin. Treatment seems to become less cost-effective when daily costs exceed $9.36 for low-dose therapy and $13.70 for high-dose therapy.
Caution
Much of the analysis relies on data from the single available manufacturer-sponsored study of dabigatran.
Implication
Depending on how it is priced, dabigatran could be a costeffective alternative to warfarin for treating atrial fibrillation.
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Cost-Effectiveness of Dabigatran for Atrial Fibrillation 2.71% with low-dose dabigatran, and 3.11% with highdose dabigatran (18, 28) . We assumed that a major hemorrhage (intracranial or major noncerebral) resulted in discontinuation of anticoagulation and replacement with aspirin. The relative risk for hemorrhage with aspirin compared with warfarin was estimated at 0.87 (30 -32) .
Stroke and Hemorrhage Severity
We classified initial ischemic stroke into 4 categories: fatal, moderate to severe neurologic sequelae, mild neurologic sequelae, and no residual neurologic deficit (Table 1 ) (28, 31, (33) (34) (35) (36) (37) (38) (39) (40) (41) . We assumed that a second mild ischemic stroke resulted in a moderate to severe ischemic stroke and that a second moderate to severe ischemic stroke resulted in death or a utility of 0. We classified hemorrhage into 6 categories: fatal, ICH with moderate to severe neurologic sequelae, ICH with mild neurologic sequelae, ICH with no residual neurologic deficit, nonfatal extracerebral major hemorrhage, and nonfatal extracerebral minor hemorrhage (Table 1) (13, 18, 32, (42) (43) (44) (45) (46) (47) . We assigned temporary decrements in quality of life (utility) for 2 days for nonfatal extracerebral minor hemorrhage and 2 weeks for nonfatal extracerebral major hemorrhage. We considered ICH either fatal or with a permanent decrement in utility due to neurologic sequelae.
Myocardial Infarction Risk
For the base case, the annual risk for myocardial infarction was 0.53% for warfarin, 0.72% for low-dose dabigatran, and 0.74% for high-dose dabigatran ( Table 1 ) (18) . The risk for myocardial infarction increased by a factor of 1.3 per decade on the basis of Framingham risk score mortality estimates for a person with the average risk factor profile of the RE-LY trial population (64) .
Quality-of-Life Estimates
To calculate quality-adjusted survival, we multiplied the probabilities of adverse events by quality-of-life estimates (utilities) (49) . We adjusted baseline quality of life by age to reflect the disutility associated with aging. We obtained the utility for warfarin without complications from published data on patients with AF that were based on patient ratings of their quality of life while receiving warfarin, including prothrombin time monitoring and changes in diet or lifestyle. The mean utility was 0.987 for warfarin (22, 65) and 0.998 for aspirin (22, 49) (Table 1) .
To estimate the utility for dabigatran, we used published estimates of utility for ximelagatran, an older direct thrombin inhibitor with similar dosing and mechanism of action. We used a utility of 0.994 for both doses of dabigatran, which was the utility for ximelagatran estimated from a survey of anticoagulation physicians (28) . This estimate was based on the disutility of taking a medication with potential adverse effects, such as bleeding, as well as the need for regular hepatic function testing required for ximelagatran. Although dabigatran does not require hepatic function testing, it is a twice-daily medication and is associated with substantial rates of dyspepsia (approximately 11%).
Costs
Costs, expressed in 2008 U.S. dollars, reflected the perspective of an ideal insurer that covered inpatient and outpatient medical care and prescription costs. This analysis excluded indirect costs. We projected costs over 35 years; future costs and life-years were discounted at 3% per year. We included age-adjusted average health care expenditures for each patient and then added the costs associated with each of the 3 treatment strategies.
Drug Treatment Costs
For warfarin, we combined the annual medication cost with the cost for 14 INR tests and the Center for Medicare & Medicaid Services (CMS) reimbursement for 90-day anticoagulation management (Current Procedural Terminology [CPT] code 99363). In sensitivity analysis, we allowed patients initiating warfarin anticoagulation to have up to 8 additional INR tests and CMS reimbursement to be at the higher rate allowed for anticoagulation initiation for 90 days (CPT code 99364) (66, 67) .
Pricing for dabigatran has not yet been established in the United States. Dabigatran is approved in the United Kingdom, Canada, and other countries for the prevention of venous thromboembolism. The price for low-dose dabigatran in the United Kingdom National Health Service is £4.20 per day (equal to $6.35 in 2008 U.S. dollars at time of analysis) (54). On the basis of historical cost ratios for other on-patent cardiovascular medications, we projected that the retail price in the United States would be 1.5 times higher than that in the United Kingdom (53, 68 -70). We estimated a price of $9.50 per day for lowdose dabigatran and $13.00 per day for high-dose dabigatran, on the basis of the dosing ratio (150:110 mg) (53, 70). We also included the costs of established care patient visits at 1 and 3 months, then every 3 months through the first year and every 4 months thereafter (18) .
Complications and Adverse Events
We estimated the 1-time costs of ischemic stroke, transient ischemic attack, ICH, and myocardial infarction on the basis of the costs of a hospitalization for the diagnosis-related group published by the Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project (59) . We estimated monthly costs of care for each complication on the basis of previously published cost estimates by using CMS reimbursement for the diagnosis-related group, adjusted to 2008 U.S. dollars, and the gross domestic product deflator (22, 56 -62) . Costs of a minor hemorrhage were based on reimbursement for an expanded problem-focused patient visit (71). We estimated the 1-time cost of a major extracranial hemorrhage on the Original Research Cost-Effectiveness of Dabigatran for Atrial Fibrillation basis of the CMS payment for the diagnosis-related group associated with gastrointestinal hemorrhage (22) .
Sensitivity Analyses
We performed 1-way sensitivity analyses of all variables included in the decision model over their plausible ranges ( Table 1) . Ranges for clinical events were derived from CIs for event rates from the RE-LY trial and from the published literature (18) . Medication costs for aspirin and warfarin included the range of discount and retail costs (53). For dabigatran, we evaluated a cost range from below the price of the medication in the United Kingdom to more than twice the cost in the United Kingdom. We derived nonmedication costs and utilities from the published literature. In 2-way sensitivity analysis, we calculated cost-effectiveness ratios of dabigatran over combinations of stroke and ICH risk.
We also conducted a sensitivity analysis in which we varied the baseline risk for stroke for all 3 treatment strategies by the same ratio to simulate the ICERs for patients with AF at lower stroke risk (CHADS 2 score, 1) and higher stroke risk (CHADS 2 score, 4). The risk ratios used were based on the published annual rate of stroke for patients with AF who were receiving warfarin with CHADS 2 scores of 1 (0.72%) and CHADS 2 scores of 4 (2.35%) relative to our base case, which was derived from the RE-LY trial with an annual stroke rate of 1.2%.
Probabilistic Sensitivity Analysis
We performed first-order Monte Carlo simulations (72) , randomly sampling (with replacement) a distribution of all variables 10 000 times and then simulating outcomes. For event rates, we generally used a normal distribution, except for the mutually exclusive subcategorization of stroke, for which we used a Dirichlet distribution. We used a ␤ distribution for utilities and ␥ and log-normal distributions for cost.
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RESULTS
Base-Case Analysis
Under base-case conditions, the quality-adjusted life expectancy was 10.28 QALYs with warfarin, 10.70 QALYs with low-dose dabigatran, and 10.84 QALYs with highdose dabigatran ( Table 2) . Total costs were $143 193 for warfarin, $164 576 for low-dose dabigatran, and $168 398 for high-dose dabigatran. The ICERs compared with warfarin were $51 229 per QALY for low-dose dabigatran and $45 372 per QALY for high-dose dabigatran. Thus, at our base-case prices, high-dose dabigatran was more costeffective than low-dose dabigatran (extended dominance).
In a hypothetical cohort of 10 000 patients with AF followed over their lifetime starting at age 65 years, lowdose dabigatran averted 1300 ICHs compared with warfarin but resulted in an additional 400 ischemic strokes (including reversible events) and 400 myocardial infarctions. High-dose dabigatran averted 1000 ICHs and 600 ischemic 
Sensitivity Analyses
One-way sensitivity analyses showed that several key variables influenced the cost-effectiveness of dabigatran (Appendix Figure 2 , available at www.annals.org), including drug cost, stroke and ICH risk for dabigatran and warfarin, age, utility of dabigatran and warfarin, costs after ICH, and utility after myocardial infarction. When we varied other model variables across plausible ranges, the ICER for high-dose dabigatran versus warfarin varied by less than $15 000 per QALY and remained less than $85 000 per QALY.
Costs
The cost of dabigatran had the greatest effect on its cost-effectiveness. At a cost greater than $9.36 per day for low-dose dabigatran, the ICER compared with warfarin exceeded $50 000 per QALY. At a cost greater than $13.70 per day for high-dose dabigatran, the ICER compared with warfarin exceeded $50 000 per QALY. When all 3 therapies were compared and the cost of high-dose dabigatran was increased from the base-case estimate of $13.00 to greater than $15.73 per day (ratio of 1.66 compared with low-dose dabigatran at its base-case cost of $9.50 per day), it no longer achieved extended dominance over low-dose dabigatran (Figure 1) .
The model was also moderately sensitive to the monthly costs of medical care for patients after ICH (Appendix Figure 2) . However, the ICER for high-dose dabigatran compared with warfarin for the full range of these costs evaluated was less than $53 880 per QALY.
Ischemic Stroke
The cost-effectiveness of high-dose dabigatran was moderately sensitive to changes in ischemic stroke rates. In a 1-way sensitivity analysis of the relative risk for stroke for high-dose dabigatran compared with warfarin, the ICER was less than $64 455 per QALY over the full range of values tested (Appendix Figure 3 , available at www.annals .org).
In a secondary analysis, we performed sensitivity analyses varying the stroke rates for the 3 therapies to simulate patients with AF at low risk (CHADS 2 score, 1) or high risk (CHADS 2 score, 4) for ischemic stroke (0.72% to 2.35% per year with warfarin) ( Table 2) . We adjusted untreated baseline stroke rates for all interventions by the same factors and held ICH rates constant at the base-case rate (0.74% per year with warfarin). For the patients at low risk for stroke (0.72% per year with warfarin), low-dose dabigatran was more cost-effective than high-dose dabigatran and cost $40 355 per QALY compared with warfarin. For patients at high risk for stroke (2.35% per year with warfarin), high-dose dabigatran was more cost-effective and cost $39 680 per QALY compared with warfarin.
Intracranial Hemorrhage
The ICER for high-dose dabigatran was moderately sensitive to changes in ICH rates in our analysis. Highdose dabigatran was more cost-effective than low-dose dabigatran over the range of ICH rates tested. In a 1-way sensitivity analysis for the relative risk for ICH for highdose dabigatran compared with warfarin, the ICER was less than $60 120 per QALY over the full range tested (Appendix Figure 3) .
We also varied the ICH rates for the 3 therapies to simulate patients with AF at low risk to high risk for ICH (0.44% to 1.48% per year with warfarin) ( Table 2) . We adjusted the ICH rates for all interventions by the same factors and held stroke rates constant at the base-case rate (1.2% per year with warfarin). For patients at low risk for ICH (0.44% per year with warfarin), high-dose dabigatran was more cost-effective than low-dose dabigatran and cost $69 574 per QALY compared with warfarin. For patients at high risk for ICH (1.48% per year with warfarin), lowdose dabigatran was more cost-effective than high-dose The slope of the cost-effectiveness line for high-dose dabigatran was lower than for low-dose dabigatran, so that at a pricing ratio Ն1.66 ($9.50 per day for low-dose and $15.73 per day for high-dose dabigatran), high-dose dabigatran no longer achieved extended dominance over low-dose dabigatran. The dotted line represents the cost-effectiveness threshold of $50 000 per QALY. At a cost Ͼ$9.36 for low-dose dabigatran, the ICER compared with warfarin exceeded $50 000 per QALY, and at a cost Ͼ$13.70 for high-dose dabigatran, the ICER compared with warfarin exceeded $50 000 per QALY. ICER ϭ incremental costeffectiveness ratio; QALY ϭ quality-adjusted life-year.
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Myocardial Infarction
In 1-way sensitivity analysis over the plausible range of myocardial infarction risk, the ICER for high-dose dabigatran versus warfarin varied by less than $11 000 per QALY and remained less than $51 000 per QALY over the entire range evaluated.
Utility
We evaluated the sensitivity of our model to changes in the utility weights of included health states. The model was most sensitive to the utility for patients receiving warfarin and the utility for patients receiving dabigatran. The ICER for dabigatran compared with warfarin remained less than $55 730 per QALY over the full range of utilities evaluated for warfarin and less than $63 360 per QALY over the full range of utilities evaluated for dabigatran (0.975 to 1.0).
Age
Using an 80-year-old patient for the base case, the quality-adjusted survival was 5.87 QALYs with warfarin, 6.24 QALYs with low-dose dabigatran, and 6.31 QALYs with high-dose dabigatran. The ICER was $27 308 per QALY for low-dose dabigatran versus warfarin, $31 168 per QALY for high-dose dabigatran versus warfarin, and $52 613 per QALY for high-dose dabigatran versus lowdose dabigatran. The ICER decreased with age because older patients had higher rates of ischemic stroke and ICH and had a larger absolute risk reduction when dabigatran was used rather than warfarin.
Two-Way Sensitivity Analyses
We performed 2-way sensitivity analyses of key variables, including one demonstrating which therapy would be preferred for varying risks for ischemic stroke and ICH. We first performed this analysis without consideration of cost and demonstrated that purely on the basis of effectiveness, high-dose dabigatran was the preferred therapy for all combinations of risk except when a patient had a very low risk for stroke and a very high risk for ICH. Using a willingness-to-pay threshold of $50 000 per QALY (Figure  2) , high-dose dabigatran was favored for the base case and for patients with a higher risk for both ischemic stroke and ICH. For patients with a low absolute risk for ischemic stroke (for example, CHADS 2 score of 0 or 1), low-dose dabigatran was the preferred therapy, especially if the concurrent ICH risk was relatively high. For patients with a low absolute risk for ICH, warfarin was the preferred therapy.
Probabilistic Sensitivity Analysis
In the Monte Carlo simulation varying all variables simultaneously, high-dose dabigatran was cost-effective in 53% of the simulations using a willingness-to-pay threshold of $50 000 per QALY and in 68% of the simulations using a willingness-to-pay threshold of $100 000 per QALY. Although low-dose dabigatran was cost-effective in fewer than 30% of the simulations at any willingness-topay threshold, it had more QALYs than high-dose dabigatran in 26% of simulations. Either high-dose or low-dose dabigatran was preferred to warfarin in more than 80% of simulations using a willingness-to-pay threshold of $50 000 per QALY and in more than 95% of simulations using a willingness-to-pay threshold of $100 000 per QALY (Figure 3) . The base-case rate of ischemic stroke and ICH for each therapy is multiplied by the same ratio, and the varying rate of events on warfarin is used as the reference. Dabigatran, 150 mg twice daily (high dose), was favored for the base case (asterisk) and for patients with a higher risk for both ischemic stroke and ICH. For patients with a low absolute risk for ischemic stroke, low-dose dabigatran was the preferred therapy, especially if the concurrent ICH risk was relatively high. For patients with a low absolute risk for ICH, warfarin was the preferred therapy. The annual rate of ischemic stroke for patients receiving warfarin with a CHADS 2 score of 1 is 0.72%, CHADS 2 score of 1-2 is 1.2%, and CHADS 2 score of 4 is 2.35%. ICH ϭ intracranial hemorrhage. 
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DISCUSSION
We demonstrated that in patients aged 65 years or older with AF who are at increased risk for stroke (CHADS 2 score Ն1 or equivalent), dabigatran could be a cost-effective alternative to warfarin. Our base-case analysis estimated a cost of $45 372 per QALY gained with highdose dabigatran compared with warfarin, which was within a range generally considered to be cost-effective (73) . High-dose dabigatran was also the most effective treatment option we evaluated, yielding an additional 0.56 QALY compared with warfarin. The cost-effectiveness of dabigatran was sensitive to drug costs and relative differences in cost between the high-and low-dose formulations, but it was relatively insensitive to other model inputs. In addition, for patients at higher risk for ischemic stroke or ICH, including those with CHADS 2 scores of 2 or greater, the ICER for high-dose dabigatran compared with warfarin improved.
Our analysis suggests that at a willingness-to-pay threshold of $50 000 per QALY, low-dose dabigatran may be the preferred therapy for patients with a low absolute risk for ischemic stroke (for example, CHADS 2 score of 0 or 1), especially if their concurrent risk for ICH is high. For patients with low absolute risk for ICH, warfarin may be the preferred therapy. However, for some low-risk patients, antiplatelet therapy rather than anticoagulation may be a reasonable alternative, but further clinical study is needed to determine optimal treatment for patients who are at low risk for stroke and ICH.
Dabigatran is the first direct thrombin inhibitor to show similar safety and efficacy to warfarin for stroke prevention in AF. Warfarin is a generic medication and prescription costs are low, but the costs of laboratory monitoring and complications due to over-and underanticoagulation are substantial. Multiple strategies to reduce costs and improve effectiveness in warfarin-treated patients, including genotype-guided warfarin dosing and patient selftesting of INR, have been evaluated. Results to date suggest that these strategies are not cost-effective for the typical patient with nonvalvular AF (74 -77). Therefore, costeffective alternatives to current methods of delivering warfarin anticoagulation are needed.
Several caveats apply to our results. First, the therapeutic efficacies and adverse event rates used in our analysis were derived mostly from the open-label RE-LY randomized, controlled trial. Follow-up of this trial cohort is ongoing (ClinicalTrials.gov registration number: NCT00808067), and clinical event rates may change with longer term follow-up. Although additional phase 3 or 4 randomized trial results are desirable, we do not know that a replication trial to This graph is based on 10 000 Monte Carlo simulations of the model, drawing parameters for each input simultaneously from probability distributions. Warfarin is most likely to be cost-effective at a willingness-to-pay threshold Յ$30 000 per QALY. At thresholds Ն$35 000 per QALY, high-dose dabigatran is most likely to be cost-effective. High-dose dabigatran is 53%, 68%, and 70% likely to be cost-effective at willingness-to-pay thresholds of $50 000, $100 000, and $150 000 per QALY, respectively. Either high-dose or low-dose dabigatran was preferred to warfarin in more than 80% of simulations using a willingness-to-pay threshold of $50 000 per QALY. QALY ϭ quality-adjusted life-year.
Original Research Cost-Effectiveness of Dabigatran for Atrial Fibrillation confirm safety and efficacy will be performed. However, a randomized trial comparing high-dose dabigatran with adjusted-dose warfarin for the treatment of acute venous thromboembolism in 2539 patients had hemorrhage rates that were very similar to those in the RE-LY trial, demonstrating a consistent risk for adverse events (78). The results of our analysis would change if future effectiveness studies provide alternative estimates for bleeding risk and stroke reduction. Second, a treatment administered in clinical practice may not be as effective as one administered in randomized trials, which generally enroll healthier patients, achieve high levels of adherence, and monitor patients more intensively (79). Finally, although dabigatran in a reduced dose of 75 mg twice daily was approved by the U.S. Food and Drug Administration for patients with creatinine clearance of 15 to 30 mL/min (19) , the RE-LY trial excluded patients with creatinine clearance less than 30 mL/min (18), so our results do not apply to that patient population.
In conclusion, we found that treatment with dabigatran could be a cost-effective alternative to adjusted-dose warfarin for stroke prevention in patients older than 65 years with nonvalvular AF at increased risk for stroke (CHADS 2 score Ն1 or equivalent). High-dose dabigatran was the most cost-effective and most effective therapy we evaluated, providing an additional 0.56 QALY over warfarin in our base-case analysis. For patients at higher risk for ischemic stroke and ICH, the ICER of dabigatran compared with warfarin improved. These results were robust over a wide range of model assumptions but were sensitive to dabigatran costs. 
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